Arca
Skip to content
Tools
Tools

NS5B: RNA-directed RNA polymerase

Protein in Hepacivirus hominis that 20 drugs act on.

  • Drugs that act on it: 20
  • Approved: 3
  • In phases 1 to 3: 17
  • Sponsors: 11

Who is on it, and how far along

Every drug ChEMBL records acting on NS5B, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 20

Approved3

  • Sofosbuvir
  • Ribavirin
  • Dasabuvir

Phase 33

  • Beclabuvir
  • Deleobuvir
  • Filibuvir

Phase 214

  • ABT-072
  • Adafosbuvir
  • Balapiravir
  • BMS-986094
  • Lomibuvir
  • Mericitabine
  • Nesbuvir
  • PSI-352938
  • Radalbuvir
  • Setrobuvir
  • Tegobuvir
  • TMC-647055
  • Uprifosbuvir
  • Valopicitabine

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 18 of 20 act as: RNA-directed RNA polymerase inhibitor; the rest name their own mechanism.
    SofosbuvirBoxed warningApprovedGilead SciencesSmall moleculeInhibitor21
    RibavirinBoxed warningApprovedBausch HealthSmall moleculeInhibitor7
    DasabuvirApprovedAbbVieSmall moleculeInhibitor0
    BeclabuvirPhase 3Bristol-Myers SquibbSmall moleculeNegative allosteric modulatorRNA-directed RNA polymerase negative allosteric modulator0
    DeleobuvirPhase 3Boehringer Ingelheim PharmaceuticalsSmall moleculeInhibitor0
    FilibuvirPhase 3PfizerSmall moleculeInhibitor0
    ABT-072Phase 2AbbVieSmall moleculeInhibitor0
    AdafosbuvirPhase 2Johnson & JohnsonSmall moleculeInhibitor0
    BalapiravirPhase 2RocheSmall moleculeInhibitor0
    BMS-986094Phase 2Bristol-Myers SquibbSmall moleculeInhibitor0
    LomibuvirPhase 2Vertex PharmaceuticalsSmall moleculeNegative allosteric modulatorRNA-directed RNA polymerase negative allosteric modulator0
    MericitabinePhase 2RocheSmall moleculeInhibitor0
    NesbuvirPhase 2Wyeth is now a wholly owned subsidiary of PfizerSmall moleculeInhibitor0
    PSI-352938Phase 2Gilead SciencesSmall moleculeInhibitor0
    RadalbuvirPhase 2Gilead SciencesSmall moleculeInhibitor0
    SetrobuvirPhase 2RocheSmall moleculeInhibitor0
    TegobuvirPhase 2Gilead SciencesSmall moleculeInhibitor0
    TMC-647055Phase 2Merck & Co. (MSD)Small moleculeInhibitor0
    UprifosbuvirPhase 2Merck & Co. (MSD)Small moleculeInhibitor0
    ValopicitabinePhase 2Merck & Co. (MSD)Small moleculeInhibitor0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 14 in all, from ClinicalTrials.gov.
    AI-Powered Hepatitis C Single-Encounter Test-and-TreatSofosbuvirPhase 4Not yet recruitingPatrick GraceAug 28, 2026
    Treatment of CKD Patients With HCVRibavirin, SofosbuvirPhase 2 / Phase 3Not yet recruitingTanta UniversityAug 18, 2026
    Sofosbuvir/Velpatasvir/Voxilaprevir Salvage Therapy in Hepatitis C Patients Who Relapsed After DAA TreatmentSofosbuvir—Active, not recruitingXiangya Hospital of Central South UniversityMay 4, 2026
    Combating Related Epidemics in HCVSofosbuvirPhase 4Not yet recruitingDuke UniversityApr 30, 2026
    SVR12 in Genotype 3 HCV (F0-F2) Treated With RDV + SOFSofosbuvir—Active, not recruitingCenter of target therapyJan 5, 2026
    Access to Hepatitis C Treatment in Cameroon: Comparison of a Simplified Test and Treat Strategy to a Standard StrategySofosbuvirPhase 4Not yet recruitingANRS, Emerging Infectious DiseasesAug 1, 2025
    C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCVSofosbuvirPhase 3Active, not recruitingAtea Pharmaceuticals, Inc.Jun 25, 2025
    Implementing Low-Barrier HCV Treatment in a Jail SettingSofosbuvirPhase 4RecruitingLifespanMay 1, 2025
    UMIT-2 - Adaptive Phase IIb Platform Trial to Determine the Efficacy and Safety of Therapeutics for CCHFRibavirinPhase 2RecruitingLiverpool School of Tropical MedicineMar 6, 2025
    Assessing Antiviral Treatments in Early Symptomatic RSVRibavirinPhase 2RecruitingUniversity of OxfordJul 5, 2024
    LAssa Fever Adjunct Treatment With DEXamethasoneRibavirinPhase 2RecruitingBernhard Nocht Institute for Tropical MedicineJan 25, 2024
    ISTH/ANRS 0409s INTEGRATE Lassa Fever StudyRibavirinPhase 2 / Phase 3RecruitingIrrua Specialist Teaching HospitalJan 18, 2024
    The Efficacy of Vosevi in Treating DAA-experienced PatientsRibavirin—RecruitingThe Third Affiliated Hospital of Guangzhou Medical UniversityDec 22, 2023
    Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)Ribavirin—RecruitingDuke UniversityFeb 20, 2020

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4296320, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.